Analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research note issued on Saturday. The brokerage set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a research note on Friday, November 15th.
Check Out Our Latest Report on Aethlon Medical
Aethlon Medical Trading Down 1.4 %
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- Following Congress Stock Trades
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How to Use the MarketBeat Excel Dividend Calculator
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What is the Nasdaq? Complete Overview with History
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
